AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Merck KGaA
Video analysis: MKKGY
All videosNo video analysis for this stock yet. Request one from our team.
News: MKKGY
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
Merck KGaA (MKKGY) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.57 per share a year ago.
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
BAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical development with Merck KGaA, Darmstadt, Germany, a leading science and technology company. Merck KGaA, Darmstadt, Germany will adopt the end-to-end capabilities of the Evinova AI-Native platform covering all modules of study design, document authoring, and downstream automation to significantly reduce ti.
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade
Merck KGaA (MKKGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
Merck KGaA (OTC:MKKGY) (OTC:MKGAF) on Thursday agreed to acquire Bio-Techne Corporation (NASDAQ:TECH) in an all-cash transaction valued at approximately $11.3 billion, as the German science and technology company seeks to expand its presence across life science research, diagnostics, and bioprocessing markets.
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
